Literature DB >> 27663591

Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer.

Irina Heid1, Katja Steiger2, Marija Trajkovic-Arsic3,4,5, Marcus Settles1, Manuela R Eßwein1, Mert Erkan6, Jörg Kleeff7, Carsten Jäger7, Helmut Friess7, Bernhard Haller8, Andreas Steingötter9, Roland M Schmid3,4, Markus Schwaiger4,10, Ernst J Rummeny1, Irene Esposito11, Jens T Siveke12,4,5, Rickmer F Braren13.   

Abstract

Purpose: Tumor heterogeneity is a hallmark of pancreatic ductal adenocarcinoma (PDAC). It determines tumor biology including tumor cellularity (i.e., amount of neoplastic cells and arrangement into clusters), which is related to the proliferative capacity and differentiation and the degree of desmoplasia among others. Given the close relation of tumor differentiation with differences in progression and therapy response or, e.g., the recently reported protective role of tumor stroma, we aimed at the noninvasive detection of PDAC groups, relevant for future personalized approaches. We hypothesized that histologic differences in PDAC tissue composition are detectable by the noninvasive diffusion weighted- (DW-) MRI-derived apparent diffusion coefficient (ADC) parameter.Experimental design: PDAC cellularity was quantified histologically and correlated with the ADC parameter and survival in genetically engineered mouse models and human patients.
Results: Histologic analysis showed an inverse relationship of tumor cellularity and stroma content. Low tumor cellularity correlated with a significantly prolonged mean survival time (PDAClow = 21.93 months vs. PDACmed = 12.7 months; log-rank P < 0.001; HR = 2.23; CI, 1.41-3.53). Multivariate analysis using the Cox regression method confirmed tumor cellularity as an independent prognostic marker (P = 0.034; HR = 1.73; CI, 1.04-2.89). Tumor cellularity showed a strong negative correlation with the ADC parameter in murine (r = -0.84; CI, -0.90- -0.75) and human (r = -0.79; CI, -0.90 to -0.56) PDAC and high preoperative ADC values correlated with prolonged survival (ADChigh = 41.7 months; ADClow = 14.77 months; log rank, P = 0.040) in PDAC patients.Conclusions: This study identifies high tumor cellularity as a negative prognostic factor in PDAC and supports the ADC parameter for the noninvasive identification of PDAC groups. Clin Cancer Res; 23(6); 1461-70. ©2016 AACR. ©2016 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2016        PMID: 27663591     DOI: 10.1158/1078-0432.CCR-15-2432

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

Review 1.  Patient-Derived Xenograft Models in Breast Cancer Research.

Authors:  Deukchae Na; Hyeong-Gon Moon
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Circulating Microvesicles from Pancreatic Cancer Accelerate the Migration and Proliferation of PANC-1 Cells.

Authors:  Mingrui An; Jianhui Zhu; Jing Wu; Kyle C Cuneo; David M Lubman
Journal:  J Proteome Res       Date:  2018-03-09       Impact factor: 4.466

3.  Scaffold-Assisted Ectopic Transplantation of Internal Organs and Patient-Derived Tumors.

Authors:  Ryan Carpenter; Hye Jeong Oh; In-Hye Ham; Daeyoung Kim; Hoon Hur; Jungwoo Lee
Journal:  ACS Biomater Sci Eng       Date:  2019-11-13

Review 4.  Fibroblasts in Pancreatic Ductal Adenocarcinoma: Biological Mechanisms and Therapeutic Targets.

Authors:  Martin C Whittle; Sunil R Hingorani
Journal:  Gastroenterology       Date:  2019-02-02       Impact factor: 22.682

5.  Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization.

Authors:  Irina Heid; Marija Trajkovic-Arsic; Fabian Lohöfer; Georgios Kaissis; Felix N Harder; Moritz Mayer; Geoffrey J Topping; Friderike Jungmann; Barbara Crone; Moritz Wildgruber; Uwe Karst; Lucia Liotta; Hana Algül; Hsi-Yu Yen; Katja Steiger; Wilko Weichert; Jens T Siveke; Marcus R Makowski; Rickmer F Braren
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-09-08       Impact factor: 10.057

6.  Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes.

Authors:  Ruli Gao; Shanshan Bai; Ying C Henderson; Yiyun Lin; Aislyn Schalck; Yun Yan; Tapsi Kumar; Min Hu; Emi Sei; Alexander Davis; Fang Wang; Simona F Shaitelman; Jennifer Rui Wang; Ken Chen; Stacy Moulder; Stephen Y Lai; Nicholas E Navin
Journal:  Nat Biotechnol       Date:  2021-01-18       Impact factor: 54.908

Review 7.  Preclinical Applications of Multi-Platform Imaging in Animal Models of Cancer.

Authors:  Natalie J Serkova; Kristine Glunde; Chad R Haney; Mohammed Farhoud; Alexandra De Lille; Elizabeth F Redente; Dmitri Simberg; David C Westerly; Lynn Griffin; Ralph P Mason
Journal:  Cancer Res       Date:  2020-12-01       Impact factor: 13.312

Review 8.  [The microarchitecture of pancreatic cancer from the point of view of the pathologist and the radiologist].

Authors:  Philipp Mayer; Matthias M Gaida
Journal:  Pathologe       Date:  2021-05-06       Impact factor: 1.011

Review 9.  The Generation and Application of Patient-Derived Xenograft Model for Cancer Research.

Authors:  Jaeyun Jung; Hyang Sook Seol; Suhwan Chang
Journal:  Cancer Res Treat       Date:  2017-09-13       Impact factor: 4.679

10.  Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma.

Authors:  M Trajkovic-Arsic; I Heid; K Steiger; A Gupta; A Fingerle; C Wörner; N Teichmann; S Sengkwawoh-Lueong; P Wenzel; A J Beer; I Esposito; R Braren; J T Siveke
Journal:  Sci Rep       Date:  2017-12-06       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.